We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.

Science

Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Month: March 2023

ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial

ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial Funding supports Phase 2 clinical study of ONL1204 Ophthalmic Solution to evaluate safety and efficacy in patients with macula-off rhegmatogenous retinal detachment ANN ARBOR, MI – March 8, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company…

March 8, 2023

Month: March 2023

ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial